Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn Into More Strength?
Baird Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $58
Guggenheim Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating
Dianthus Started at Outperform by Oppenheimer on DNTH103 Opportunity
Oppenheimer Initiates Dianthus Therapeutics at Outperform With $48 Price Target
Express News | Dianthus Therapeutics Files for Resale of up to 23.7 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $40
Promising Outlook for Dianthus Therapeutics' DNTH103 as a Best-in-Class C1s Inhibitor
Hesperos Provides Support for an Investigational Product for a Phase II Clinical Trial With Its Human-on-a-Chip
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
J&J Submits FDA Application for Myasthenia Gravis Drug Nipocalimab
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Nuvalent (NUVL) and Dianthus Therapeutics (DNTH)
HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target
Promising Clinical Developments Bolster Buy Rating for Dianthus Therapeutics
Dianthus Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Wedbush Remains a Buy on Dianthus Therapeutics (DNTH)
Dianthus Therapeutics Receives 'Buy' Rating on Strong Financials and Promising Drug Pipeline
Express News | Dianthus Therapeutics Inc : Wedbush Cuts Target Price to $36 From $38
Dianthus Therapeutics GAAP EPS of -$0.51 Beats by $0.04